Capstan Therapeutics to Present Preclinical Data on CAR-T Candidate CPTX2309 at ACR Convergence 2024

Capstan Therapeutics, Inc., a biotechnology company focused on advancing cell reprogramming through RNA delivery via their CellSeeker™ targeted lipid nanoparticle (tLNP) technology, has announced the presentation of preclinical data on their lead CAR-T candidate, CPTX2309. The presentation is scheduled for the American College of Rheumatology (ACR) Convergence 2024, to be held from November 14-19, 2024, in Washington, D.C.

CPTX2309 leverages the CellSeeker™ platform to deliver mRNA encoding an anti-CD19 CAR specifically to CD8-expressing T cells. This innovative approach aims to reset the immune system by achieving rapid and profound B cell depletion in blood and lymphatic tissues without the challenges of conventional ex vivo CAR-T therapies.

Dr. Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D at Capstan, highlighted the potential of Capstan's non-viral in vivo CAR-T method. He noted that it combines the remarkable efficacy of CAR-T therapy with the ease of use, pharmacological adjustability, and scalability of traditional biologics. According to Dr. Bot, the data to be presented will support the development of CPTX2309 for a wide range of B cell-mediated autoimmune diseases, with the ultimate goal of resetting a patient's immune system to achieve a lasting, drug-free clinical response.

The presentation details are as follows:

- Abstract ID: 0835
Title: Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid Nanoparticle Encoding an Anti-CD19 CAR mRNA (CPTX2309)
Presentation Type: Oral Presentation
Presenting Author: Dr. Haig Aghajanian, Co-Founder, Head, and Vice President of Research at Capstan Therapeutics
Session: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date and Time: Saturday, November 16, 3:00 PM – 3:15 PM ET

- Abstract ID: 0088
Title: Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Presentation Type: Poster
Presenting Author: Dr. Aric Frantz, Senior Director of Pharmacology and Toxicology at Capstan Therapeutics
Session: SLE – Animal Models Poster
Date and Time: Saturday, November 16, 10:30 AM – 12:30 PM ET

- Abstract ID: 0019
Title: A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Presentation Type: Poster
Presenting Author: Dr. Theresa Hunter, Principal Scientist at Capstan Therapeutics
Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Date and Time: Saturday, November 16, 10:30 AM – 12:30 PM ET

The presented posters and presentations will be accessible in the “Publications and News” section of Capstan’s website following the conference.

Capstan Therapeutics, Inc. is committed to expanding therapeutic possibilities through targeted in vivo RNA technologies. Their proprietary CellSeeker™ tLNP platform uses novel lipid nanoparticles conjugated with recombinant protein binders, such as monoclonal antibodies, to deliver payloads, including mRNA or gene editing tools, for reprogramming specific cell types in vivo. This technology has the potential to create transformative therapies across various disease areas including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.